Bristlecone Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $1.26M | Sell |
49,316
-26,177
| -35% | -$646K | 0.11% | 117 |
|
|
2025
Q2 | $1.83M | Sell |
75,493
-125,972
| -63% | -$2.94M | 0.15% | 105 |
|
|
2025
Q1 | $5.11M | Buy |
201,465
+34,550
| +21% | +$904K | 0.42% | 54 |
|
|
2024
Q4 | $4.43M | Buy |
166,915
+50,359
| +43% | +$1.37M | 0.35% | 59 |
|
|
2024
Q3 | $3.37M | Buy |
116,556
+25,281
| +28% | +$737K | 0.27% | 74 |
|
|
2024
Q2 | $2.55M | Buy |
91,275
+22,637
| +33% | +$623K | 0.22% | 92 |
|
|
2024
Q1 | $1.9M | Buy |
68,638
+58,092
| +551% | +$1.61M | 0.17% | 107 |
|
|
2023
Q4 | $304K | Sell |
10,546
-29
| -0.3% | -$877 | 0.03% | 225 |
|
|
2023
Q3 | $351K | Buy |
10,575
+30
| +0.3% | +$1.06K | 0.04% | 196 |
|
|
2023
Q2 | $387K | Buy |
10,545
+511
| +5% | +$19.9K | 0.04% | 196 |
|
|
2023
Q1 | $409K | Sell |
10,034
-968
| -9% | -$41.8K | 0.04% | 188 |
|
|
2022
Q4 | $564K | Buy |
11,002
+341
| +3% | +$16.3K | 0.07% | 160 |
|
|
2022
Q3 | $467K | Buy |
10,661
+321
| +3% | +$15.6K | 0.06% | 169 |
|
|
2022
Q2 | $542K | Sell |
10,340
-37
| -0.4% | -$1.89K | 0.07% | 161 |
|
|
2022
Q1 | $537K | Buy |
10,377
+36
| +0.3% | +$1.87K | 0.07% | 154 |
|
|
2021
Q4 | $611K | Buy |
10,341
+93
| +0.9% | +$4.61K | 0.07% | 152 |
|
|
2021
Q3 | $441K | Sell |
10,248
-494
| -5% | -$21.9K | 0.06% | 159 |
|
|
2021
Q2 | $421K | Sell |
10,742
-47
| -0.4% | -$1.83K | 0.06% | 157 |
|
|
2021
Q1 | $391K | Sell |
10,789
-1,791
| -14% | -$63.6K | 0.06% | 157 |
|
|
2020
Q4 | $463K | Sell |
12,580
-554
| -4% | -$20.3K | 0.07% | 144 |
|
|
2020
Q3 | $457K | Buy |
13,134
+1,282
| +11% | +$44.9K | 0.08% | 132 |
|
|
2020
Q2 | $368K | Sell |
11,852
-1,752
| -13% | -$59.5K | 0.07% | 136 |
|
|
2020
Q1 | $421K | Sell |
13,604
-18,972
| -58% | -$646K | 0.1% | 121 |
|
|
2019
Q4 | $1.21M | Buy |
32,576
+18,718
| +135% | +$667K | 0.24% | 97 |
|
|
2019
Q3 | $472K | Sell |
13,858
-19,257
| -58% | -$700K | 0.11% | 114 |
|
|
2019
Q2 | $1.36M | Buy |
33,115
+18,781
| +131% | +$746K | 0.32% | 76 |
|
|
2019
Q1 | $578K | Buy |
14,334
+2,895
| +25% | +$116K | 0.16% | 92 |
|
|
2018
Q4 | $474K | Buy |
11,439
+64
| +0.6% | +$2.66K | 0.14% | 106 |
|
|
2018
Q3 | $476K | Buy |
11,375
+5,190
| +84% | +$200K | 0.12% | 110 |
|
|
2018
Q2 | $213K | Sell |
6,185
-1,680
| -21% | -$57.4K | 0.07% | 128 |
|
|
2018
Q1 | $265K | Sell |
7,865
-3,717
| -32% | -$128K | 0.09% | 120 |
|
|
2017
Q4 | $398K | Buy |
11,582
+166
| +1% | +$5.66K | 0.13% | 116 |
|
|
2017
Q3 | $387K | Sell |
11,416
-1,317
| -10% | -$42.3K | 0.13% | 109 |
|
|
2017
Q2 | $406K | Sell |
12,733
-779
| -6% | -$24.6K | 0.14% | 112 |
|
|
2017
Q1 | $439K | Sell |
13,512
-451
| -3% | -$14.2K | 0.15% | 108 |
|
|
2016
Q4 | $430K | Sell |
13,963
-1,901
| -12% | -$58K | 0.15% | 109 |
|
|
2016
Q3 | $510K | Sell |
15,864
-4,737
| -23% | -$158K | 0.18% | 106 |
|
|
2016
Q2 | $688K | Sell |
20,601
-3,469
| -14% | -$111K | 0.25% | 88 |
|
|
2016
Q1 | $677K | Buy |
24,070
+3,395
| +16% | +$97K | 0.27% | 90 |
|
|
2015
Q4 | $633K | Buy |
+20,675
| New | +$650K | 0.27% | 95 |
|
Other funds holding PFE
Bristlecone Advisors's PFE Position: Q3 2025 in Review
Bristlecone Advisors reduced its Pfizer (PFE) stake by 35% in Q3 2025, selling an estimated $646K and leaving 49,316 shares worth $1.26M. The position accounts for 0.11% of the portfolio, ranked #117.
Bristlecone Advisors first reported a position in PFE in Q4 2015 and has held it in 40 quarters since. The position peaked at $5.11M in Q1 2025. 2,811 funds tracked by Wall St. Rank hold PFE as of Q3 2025.
- Bristlecone Advisors held 49,316 shares of Pfizer worth $1.26M as of Q3 2025.
- Bristlecone Advisors sold 26,177 Pfizer shares in Q3 2025, an estimated $646K.
- Pfizer made up 0.11% of Bristlecone Advisors's portfolio in Q3 2025, its #117 holding.
- Bristlecone Advisors first reported a position in Pfizer in Q4 2015 and has held it in 40 quarters since.
- Bristlecone Advisors's Pfizer position peaked at $5.11M in Q1 2025.
- 2,811 funds tracked by Wall St. Rank held Pfizer as of Q3 2025.
Based on Bristlecone Advisors's 13F filing for Q3 2025, filed 24 Oct 2025.